TScan Therapeutics, Inc. — Director's Dealing 2021

Sep 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-09-09

Reporting Person: Silver Brian M. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-09	Voting Common Stock	P	5885	$8.4835	Acquired	6885	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $8.34 to $8.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.